Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vickerman

Showing results (231-240 of 397) with videos related to

Pageof 40
Sort By:
BMJ Open|August 28, 2020
On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017Christer Frode Aas, Jørn Henrik Vold, Svetlana Skurtveit, et al.
Addiction (Abingdon, England)|January 24, 2019
Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugsSedona Sweeney, Zoe Ward, Lucy Platt, et al.
PLOS Global Public Health|April 5, 2023
Cost-effectiveness of Hepatitis C virus self-testing in four settingsJosephine G Walker, Elena Ivanova, Muhammad S Jamil, et al.
Annals of Epidemiology|July 17, 2016
Data and methods to characterize the role of sex work and to inform sex work programs in generalized HIV epidemics: evidence to challenge assumptionsSharmistha Mishra, Marie-Claude Boily, Sheree Schwartz, et al.
The Journal of Infectious Diseases|March 30, 2012
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study designPeter Vickerman, Jason Grebely, Gregory J Dore, et al.
The International Journal on Drug Policy|February 21, 2026
Optimal provision of opioid agonist therapy (OAT) and needle and syringe programmes (NSP): a realist evaluationPeter McCulloch, Hannah Family, April Shaw, et al.
Plos One|October 2, 2014
Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South IndiaJasmina Panovska-Griffiths, Anna Vassall, Holly J Prudden, et al.
AIDS (London, England)|September 11, 2015
Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in NigeriaKate M Mitchell, Aurélia Lépine, Fern Terris-Prestholt, et al.
Ebiomedicine|March 18, 2023
The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling studyJack Stone, Katharine Jane Looker, Romain Silhol, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2013
Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal studyAndrea J Low, Issouf Konate, Nicolas Nagot, et al.
Pageof 40

Showing results (231-240 of 397) with videos related to

Sort By:
Pageof 40
BMJ Open|August 28, 2020
On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017Christer Frode Aas, Jørn Henrik Vold, Svetlana Skurtveit, et al.
Addiction (Abingdon, England)|January 24, 2019
Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugsSedona Sweeney, Zoe Ward, Lucy Platt, et al.
PLOS Global Public Health|April 5, 2023
Cost-effectiveness of Hepatitis C virus self-testing in four settingsJosephine G Walker, Elena Ivanova, Muhammad S Jamil, et al.
Annals of Epidemiology|July 17, 2016
Data and methods to characterize the role of sex work and to inform sex work programs in generalized HIV epidemics: evidence to challenge assumptionsSharmistha Mishra, Marie-Claude Boily, Sheree Schwartz, et al.
The Journal of Infectious Diseases|March 30, 2012
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study designPeter Vickerman, Jason Grebely, Gregory J Dore, et al.
The International Journal on Drug Policy|February 21, 2026
Optimal provision of opioid agonist therapy (OAT) and needle and syringe programmes (NSP): a realist evaluationPeter McCulloch, Hannah Family, April Shaw, et al.
Plos One|October 2, 2014
Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South IndiaJasmina Panovska-Griffiths, Anna Vassall, Holly J Prudden, et al.
AIDS (London, England)|September 11, 2015
Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in NigeriaKate M Mitchell, Aurélia Lépine, Fern Terris-Prestholt, et al.
Ebiomedicine|March 18, 2023
The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling studyJack Stone, Katharine Jane Looker, Romain Silhol, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2013
Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal studyAndrea J Low, Issouf Konate, Nicolas Nagot, et al.
Pageof 40